Gupta S, Masand P S, Kaplan D, Bhandary A, Hendricks S
Omaha VAMC, NE, USA.
Schizophr Res. 1997 Feb 28;23(3):265-8. doi: 10.1016/s0920-9964(96)00099-0.
Irritable bowel syndrome (IBS) has been reported in 10-22% of adults. Amongst patients seeking medical attention for IBS 70-90% may have psychiatric co-morbidity, most commonly major depression. In contrast, few studies have looked at the prevalence of IBS in psychiatric patients. To our knowledge, there are no studies assessing the prevalence of IBS in patients with schizophrenia. Using a semistructured clinical interview to study the prevalence of IBS, we compared 47 patients with schizophrenia to an age-matched control group (n = 40) of patients who were seeking treatment in a primary care physicians office for other medical illnesses. IBS was diagnosed according to the criteria of Drossman et al. Nineteen percent (n = 9) of the patients with schizophrenia met criteria for IBS in contrast to 2.5% (n = 1) of the control group (p = 0.012). Schizophrenic patients seldom complain of gastrointestinal symptoms until specifically asked. Therefore, it may be important to inquire about gastrointestinal symptoms prior to initiating pharmacotherapy in order to differentiate side effects from a prior existing condition. Prospective studies should address the question whether remission of psychosis leads to improvement or resolution of IBS.
据报道，10%-22%的成年人患有肠易激综合征（IBS）。在因IBS就医的患者中，70%-90%可能合并有精神疾病，最常见的是重度抑郁症。相比之下，很少有研究关注精神疾病患者中IBS的患病率。据我们所知，尚无评估精神分裂症患者中IBS患病率的研究。我们采用半结构式临床访谈来研究IBS的患病率，将47例精神分裂症患者与一个年龄匹配的对照组（n = 40）进行比较，对照组为在初级保健医生办公室因其他疾病就诊的患者。IBS根据德罗兹曼等人的标准进行诊断。19%（n = 9）的精神分裂症患者符合IBS标准，而对照组为2.5%（n = 1）（p = 0.012）。精神分裂症患者很少主动诉说胃肠道症状，除非被特意询问。因此，在开始药物治疗前询问胃肠道症状，以区分副作用和既往存在的疾病可能很重要。前瞻性研究应探讨精神病症状缓解是否会导致IBS改善或缓解这一问题。
